Philip Breitfeld, MD

Dr. Breitfeld has led development and project teams focusing on phase 1, Proof of Concept, and Pivotal trials in oncology. He has had pharmaceutical development experience in solid tumors (CRC, NSCLC, prostate, breast, SCCHN, pancreatic, renal cell carcinoma, gastric, GBM, and melanoma) and malignant hematology, including leading oncology development at both small biotechs and midsized global pharma companies. In his four years at IQVIA (Quintiles), he developed and led the Oncology Center of Excellence- the matrix organization that drives the long-term business agenda for oncology at IQVIA.

He earned his M.D. from the University of Rochester School of Medicine, where he completed his pediatric residency. He completed fellowships in pediatric hematology-oncology and medical informatics at Harvard Medical School and the Indiana University School of Medicine. Prior to entering the industry, he was on the faculty at Duke University Medical Center, the Indiana School of Medicine, and the University of Massachusetts Medical School.